Modern (MRNA) – Get report it increased after Jefferies analyst Michael Yee began coverage of the biopharmaceutical company with a buy rating and a stock price target of $ 90, and Nasdaq said it would add the shares to the Nasdaq 100. The company’s coronavirus vaccine candidate could sell for …
Read More »
The 2020 coronavirus and the 1918 Spanish influenza pandemics share many similarities, but also diverge on one key point. “A big difference between the Spanish flu and COVID-19 is the age distribution of deaths,” according to Deutsche Bank DB, + 4.40%. “For COVID-19, the elderly have been overwhelmingly the most …
Read More »
Former FDA chief Scott Gottlieb, left, and former Secretary of Health and Human Services Michael Leavitt, center, are advising Royal Caribbean and Norwegian on security protocols for navigating the pandemic era. Royal Caribbean CEO Richard Fain says the findings will be made public. Getty Images (1); Bloomberg (2) Text size …
Read More »
One expert cautioned that relying on immunity to Covid-19 as a strategy to deal with the pandemic is not a “safe bet,” adding that mass immunity strategies “will probably never work.” Speaking to CNBC’s “Squawk Box Europe” on Monday, Danny Altmann, professor of immunology at Imperial College London, said that …
Read More »
Moderna’s MRNA shares were lower after a news report said biotechnology was delaying the start of a Phase III trial of its experimental coronavirus vaccine. Shares of the Cambridge, Massachusetts company in the latest check fell 5.4% to $ 58.25. Healthcare website Stat News said Moderna was making changes to …
Read More »